Oncotarget

Research Papers:

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides

Siau Jia Wei, Sharon Chee, Larisa Yurlova, David Lane, Chandra Verma, Christopher Brown and Farid Ghadessy _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:32232-32246. https://doi.org/10.18632/oncotarget.8572

Metrics: PDF 1226 views  |   HTML 1991 views  |   ?  


Abstract

Siau Jia Wei1, Sharon Chee1, Larisa Yurlova3, David Lane1, Chandra Verma2,4,5, Christopher Brown1, Farid Ghadessy1

1P53 Laboratory (A*STAR), #06-04/05 Neuros, 138648, Singapore

2Bioinformatics Institute (A*STAR), 07-01 Matrix, 138671, Singapore

3ChromoTek GmbH, 82152 Planegg-Martinsried, Germany

4School of Biological Sciences, Nanyang Technological University, 637551, Singapore

5Department of Biological Sciences, National University of Singapore, 117543, Singapore

Correspondence to:

Farid Ghadessy, email: fghadessy@p53Lab.a-star.edu.sg

Keywords: p53, HDM2, MDM2, stapled peptide, cancer resistance

Received: November 11, 2015     Accepted: March 18, 2016    Published: April 4, 2016

ABSTRACT

Cancer drugs often fail due to the emergence of clinical resistance. This can manifest through mutations in target proteins that selectively exclude drug binding whilst retaining aberrant function. A priori knowledge of resistance-inducing mutations is therefore important for both drug design and clinical surveillance. Stapled peptides represent a novel class of antagonists capable of inhibiting therapeutically relevant protein-protein interactions. Here, we address the important question of potential resistance to stapled peptide inhibitors. HDM2 is the critical negative regulator of p53, and is often overexpressed in cancers that retain wild-type p53 function. Interrogation of a large collection of randomly mutated HDM2 proteins failed to identify point mutations that could selectively abrogate binding by a stapled peptide inhibitor (PM2). In contrast, the same interrogation methodology has previously uncovered point mutations that selectively inhibit binding by Nutlin, the prototypical small molecule inhibitor of HDM2. Our results demonstrate both the high level of structural p53 mimicry employed by PM2 to engage HDM2, and the potential resilience of stapled peptide antagonists to mutations in target proteins. This inherent feature could reduce clinical resistance should this class of drugs enter the clinic.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8572